Summary Objective: To assess the value of Cyfra 21-1, carcino-embryonic antigen (CEA) and neuron-specific enolase (NSE) combined, all three together as prognostic factors in advanced stage non-small cell lung cancer (NSCLC) patients.
Introduction
Lung cancer is the major cause of cancer-related death in western countries. Research on prognostic factors in non-small cell lung cancer (NSCLC) is of great importance because it potentially leads to a better and perhaps tailored management of patients. Some serum markers are potential prognostic factors in NSCLC patients. However, serum markers are interesting if they give a supplementary and independent information on prognosis which is currently principally based on Performans Status (PS) and TNM classification. 1 Increased level of a recognized and independent marker should be able to modify the therapeutic strategy as for nodal or metastatic status for example. None of the markers is actually considered when deciding treatment option.
Among these NSCLC markers Cyfra 21-1, a fragment of cytokeratin subunit 19, is of great interest. Indeed, Cyfra 21-1 was found in several studies to be correlated with TNM stage and PS and reflecting prognosis of NSCLC patients in an independent manner. [2] [3] [4] [5] [6] [7] Then, Pujol and others suggested that Cyfra 21-1 should be regarded as a co-variable in future NSCLC trials. 2 Neuron-specific enolase (NSE) was evaluated in NSCLC and high NSE level was found to be of poor prognosis. 8 High NSE level could reflect a neuroendocrine component in NSCLC leading to better response to chemotherapy 9 but poorest outcome. However, prognostic implication of NSE in NSCLC patients management has to be clearly specified.
Carcino-embryonic antigen (CEA) is currently not considered in prognostic evaluation of NSCLC patients given the results of previous studies. 10, 11 Nevertheless, discordance persists between authors, and CEA could be useful under particular conditions such as response evaluation or resected patients. 12, 13 In this study, we hypothesize that combination of Cyfra 21-1, CEA and NSE considered together could have a better prognostic value in NSCLC than each of them considered separately.
Patients and methods

Patients
Serum samples from untreated lung cancer patients were prospectively collected from January 1994 to December 2000. Eligibility criteria consisted of histologically or cytologically proven NSCLC. Patients suffering from small cell lung cancer were not eligible. Histological subclassification was done according to the World Health Organization classification.
14 PS was estimated using the Eastern Cooperative Oncology Group scale. Clinical examination, chest, abdomen and brain computed tomographic scan, bronchoscopy and bone scanning were carried out systematically. Staging was done upon these procedures according to the TNM classification. 15 
Treatments
A medical panel composed of thoracic surgeons, chest physicians and radiotherapists examined each patient's record. Treatments were decided according to the standard of care. Stage IIIB patients were generally treated using an association of sequential chemotherapy (cisplatin and etoposide) and thoracic radiotherapy (60 grays in 30 fractions), while stage IV patients received platinum-based chemotherapy (with vinorelbine, gemcitabine or paclitaxel) for a maximum of six cycles.
Biochemical measurements
Serum samples were obtained from each patient before initiation of treatment. Fresh serum was collected and cooled after sampling, than stored at À201C until dosage. All assays were performed using commercial kits (ELSA 2 CEA CisBiointernationalt; ELSA Cyfra 21-1 CisBiointernationalt; NSERia Pharmaciat) blind to clinical information.
Serum levels of CEA, NSE and Cyfra 21-1 were considered as elevated when they were superior or equal to 10, 13 and 3.5 ng/ml, respectively. Cut-off value of 10 ng/ml for CEA was determined according to our previous findings. 12 Cut-off values of 3.5 ng/ml for Cyfra 21-1 and 13 ng/ml for NSE were based on previously published results. 2, 8, 9 Statistics Survival data were updated in July 2003. One patient was lost. Probability of survival was estimated using the Kaplan-Meier method. Differences between survival were tested by means of log-rank test. A multivariate regression analysis was done with Cox's regression using the forward maximum likelihood method. All variables with a pvalue less than 0.20 at the time of univariate analysis were entered into the model. A p-value less than 0.05 was considered as significant.
Results
Patients characteristics
Overall, 264 patients with a median age of 62 years (range, 27-85 years) were studied. Demographic data and clinical characteristics of patients are summarized in Table 1 . One hundred and eleven patients (41.8%) had serum level of CEA410 ng/ml, 87 (33.2%) had NSE level413 ng/ml and 138 (52.5%) had Cyfra 21-1 level43.5 ng/ml. Table 2 summarize the results for the various combinations of all the three serum markers measurements.
Survival analysis
Survival was analyzed in the whole patient population. Median follow-up was 9 months [range, 1-77 months]. There were 261 events and median survival was 9 months [range, . A significant difference (p ¼ 0.0001) was seen between the seven categories. In univariate analysis, age (o65 versus X65 years, p ¼ 0.01), PS (0/1 versus 2, po0.00001) and TNM (stage IIIB versus IV, p ¼ 0.01) showed statistically significant influence on prognosis. Serum level of Cyfra 21-1 (o3.5 versus X3.5 ng/ml, p ¼ 0.0001) considered alone or (Table 5) .
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Discussion
Several serum markers were tested in NSCLC patients and proved to be of low value. Indeed, only Cyfra 21-1 clearly independently predicts survival. In this study, we hypothesize that combination of Cyfra 21-1, CEA and NSE considered together could have a better prognostic value than each of them considered separately. We showed differences in survival between patients with normal and high level of Cyfra 21-1 (p ¼ 0.0001) but not CEA or NSE considered alone. Considered all three together, Cyfra 21-1, CEA and NSE highly correlated with survival in univariate analysis (p ¼ 0.0001). Furthermore, Cyfra 21-1 reached statistical significance in multivariate analysis (p ¼ 0.01) as well as the combination of the three tumor markers considered together (p ¼ 0.02). Considering the three markers together, adding NSE and CEA to Cyfra 21-1 demonstrated an independent value in prognostic evaluation. A significant additive value of CEA and Cyfra 21-1 in lung adenocarcinoma was showed by Ando and colleagues. 17 Indeed, high levels of both these markers were correlated with advanced stage of disease. However, prognostic significance of CEA is discussed for a long time with conflicting results. Indeed, some studies showed a negative prognostic value for CEA 7, 18 while others did not. [19] [20] [21] These discrepancies probably highlight the need for specific evaluation of CEA in distinct subgroups according to histology 22 or stage of disease. 17 Prognostic value of high NSE level did not reach statistical significance neither in univariate (p ¼ 0.08) nor in multivariate analysis. This was in discrepancy with previous studies. 3, 8, 9 Indeed, we applied a cut-off value of 13 ng/ml in accordance with previously published study. 3, 8, 9 However, a better specificity for NSCLC could be obtained with a cut-off value of 20 ng/ml 16 but decreasing sensibility (i.e. the number of patients with high NSE level). Then, the choice of the most suitable cut-off value for NSE in the setting of NSCLC has to be discussed. Prognostic value of Cyfra 21-1 was confirmed with a significant relation with survival in multivariate analysis as reported before. [2] [3] [4] [5] [6] Moreover, we confirmed the optimal cut-off of 3.5 ng/ml value for Cyfra 21-1 in prognostic evaluation. 2, 3 Grouped analysis of different markers, each associated with a possible prognostic value, should be again investigated because potentially improving prognostic information 23 and use of mathematical tools in this setting could be helpful and more powerful. 24 Regarding our results, more studies of several blood molecules as prognostic markers are needed including previously proposed biological markers such as lactate dehydrogenase, alkaline phosphatase, albumin, serum sodium, hemoglobin and leukocytes in the aim to select the most suitable co-variables for clinical trials. 25 Nevertheless, despite their independent prognostic value, neither Cyfra 21-1 nor the combination of Cyfra 21-1 with CEA and NSE actually influence the therapeutic strategy. However, their impact on the assessment of the efficacy of the chemotherapy was demonstrated. 26, 27 Indeed, the decrease of Cyfra 21-1 level after one cycle of chemotherapy could predict the clinical and radiological response. In this way, initial serum markers level is significantly correlated with survival and its evolution could lead to the chemotherapy regimen adaptation. Then, more studies in this setting are needed.
ARTICLE IN PRESS
